MediaValet Announces Grant of Options

VANCOUVER, BC -- (Marketwired) -- 06/14/17 -- MediaValet Inc. (TSX VENTURE: MVP) (the "Company") announced today that it has issued 550,000 stock options to certain employees and directors of the Company. The options are being offered in conformance with TSX Venture Exchange regulations as incentive compensation. The options have a term of five years and an exercise price of $0.09 per share.

Following the issuance, the Company has 7,890,664 incentive stock options outstanding. As approved at the June 16, 2016 annual general meeting, the Company's Stock Option Plan allows the Board to issue the equivalent of up to 10% of the issued and outstanding share capital of the Company on a rolling basis.

About MediaValet, Inc.

MediaValet stands at the forefront of the cloud-based digital asset management industry. Built exclusively on Microsoft Azure and available on 34 highly secure and hyper scalable data centers around the world, MediaValet is uniquely equipped to meet the digital asset management needs of any organization, no matter its size, its industry or its location. Cutting-edge technology, exceptional product design, and unlimited friendly customer service are at the core of MediaValet's DNA -- ensuring exceptional customer and user experiences are delivered at all times. Learn more at www.mediavalet.com.

Follow MediaValet: Blog, Twitter and LinkedIn

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

   For further information, please contact:David [email protected](604) 688-2321Babak PedramInvestor [email protected](416) 644-5081

Source: MediaValet, Inc.

You May Also Be Interested In

• Raceway Jeep Launches Grand Opening Celebration with 2026 Jeep Wrangler Giveaway
• Intrepid Metals Advances Porphyry Targeting at Corral Ahead of Integrated Geophysical Survey and Planned Q3 Drill Program
• Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma